ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%

ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34% Fierce Pharma A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China CNBC Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer statnews.com Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China Yahoo Finance Lung Cancer Patients on Drug From China’s Akeso Lived Longer Bloomberg.com